Search clinical trials for: Antineoplastic Agents, Immunological

Total 65883 results

University of Birmingham
Regeneron Pharmaceuticals; Cancer Research UK; Fight Kids Cancer; ADC Therapeutics...

Not yet recruiting

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

B-cell Non Hodgkin Lymphoma
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...
Chinese Academy of Medical Sciences Cancer Hospital，Shanxi Center; Chinese... and other collaborators

Not yet recruiting

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Breast Cancer | Neoadjuvant Therapy

China
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

Metastatic Non-small Cell Lung Cancer

Australia, United Kingdom, Korea, Republic of, Belgium, Canada, Germany, Italy, Spain, Argentina, United States, Brazil, China, India, Japan, Taiwan, France, Thailand, Turkey, Mexico, Hungary, South Africa, Poland, Austria, Czechia, Slo... and more
Affiliated Cancer Hospital of Shantou University...

Recruiting

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Second... and other collaborators

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
Inspirna, Inc.

Recruiting

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Colorectal Cancer | Metastatic Colon Cancer

Belgium, Spain, France
NYU Langone Health

Recruiting

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Pancreatic Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

Healthy Participants

United States
The Netherlands Cancer Institute
AstraZeneca; Daiichi Sankyo

Recruiting

Basket Study for Oligo-metastatic Breast Cancer (ANISE)

HER2-positive Breast Cancer

Netherlands
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Gastric Cancer

China
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
InxMed (Shanghai) Co., Ltd.

Not yet recruiting

IN10018 Combination Therapy in Previously-treated Solid Tumors

Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC (HNC-SYSU-002)

Oral Cancer | HNSCC | PD-1

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Washington University School of Medicine
Eli Lilly and Company

Recruiting

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

Recurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
HuiKai Li

Not yet recruiting

Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

Hepatocellular Carcinoma

China
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy (FIL_Tisle-HL)

Hodgkin Lymphoma

Italy
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Tel Aviv Medical Center

Not yet recruiting

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

GBM
Idelberto Badell
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Subcutaneous Abatacept in Renal Transplant Recipients (RTB-016)

Kidney Transplant Recipient

United States
UNICANCER

Not yet recruiting

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA)

Triple Negative Breast Neoplasms
Mayur Narkhede
ADC Therapeutics S.A.

Recruiting

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Bevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutated

China
Peking University Cancer Hospital & Institute

Recruiting

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Breast Neoplasm Female

China
Fudan University

Recruiting

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research

Not yet recruiting

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Breast Cancer

Canada
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Affiliated Hospital of Nantong University

Not yet recruiting

Obinutuzumab in Chinese Real-world Patients With iNHL

Lymphomas Non-Hodgkin's B-Cell

China
University of Colorado, Denver
Cancer League of Colorado

Recruiting

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus (NEOPAX)

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Inferior Vena Cava Thrombosis

United States
Genentech, Inc.
BioNTech SE

Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

Adenocarcinoma, Pancreatic Ductal

United States, United Kingdom, France, Canada, Sweden, Spain
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Ovarian Cancer
University of Southampton
AstraZeneca; Natera, Inc.

Recruiting

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER)

Gastrooesophageal Cancer

United Kingdom
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals

Recruiting

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Colon Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Niels Junker
Karolinska University Hospital; Oslo University Hospital; Aarhus University Hospital

Recruiting

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (PROPANE)

Soft Tissue Sarcoma Adult | Angiosarcoma | Undifferentiated Pleomorphic Sarcoma

Norway, Sweden, Denmark
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma (GALAXY-1)

Neoplasms | Antineoplastic Agents | Carcinoma, Squamous

China

Search clinical trials for: Antineoplastic Agents, Immunological

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations